Allied Corp. (ALID) Stock Analysis

Allied Corp. (ALID) Healthcare & Pipeline Overview

Allied Corp. specializes in the research and production of cannabinoid health solutions, offering a range of hemp-derived products while navigating the evolving landscape of the medical cannabis industry.

What Is the Investment Thesis for ALID?

Allied Corp. presents a unique investment thesis driven by its innovative product portfolio and strategic focus on cannabinoid health solutions. With a market cap currently at $0.00B and a profit margin of -14807.6%, the company is in a critical phase of development, particularly with its ALID 10 and ALID 11 products targeting PTSD, which could tap into a significant and underserved market. The U.S. medical cannabis market is projected to grow substantially, driven by increasing acceptance and regulatory changes. As the company continues to refine its product offerings and expand its distribution channels, it is poised to capture a larger share of this expanding market. However, investors should remain cognizant of the inherent risks associated with the cannabis industry, including regulatory challenges and market volatility. Monitoring these factors will be essential to assess the company's ability to achieve its growth objectives and improve financial performance.

Based on FMP financials and quantitative analysis

ALID Key Highlights

Market cap currently at $0.00B reflects early-stage development in the cannabis industry.

• Profit margin of -14807.6% indicates significant investment in growth and product development.
• Gross margin of -2027.5% highlights the challenges in scaling operations and achieving profitability.
• Diverse product portfolio includes CBD tinctures, gummies, and topical applications targeting various health needs.
• Ongoing Phase I clinical trials for ALID 10 and ALID 11 represent potential future revenue streams.

Who Are ALID's Competitors?

ALID is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ALID's Key Strengths?

Innovative product offerings tailored to consumer health needs.

• Strong focus on research and development for new therapeutic solutions.
• Established presence in the growing medical cannabis market.
• Diverse product portfolio enhancing market reach.

What Are ALID's Weaknesses?

Negative profit margins indicating financial challenges.

• Limited brand recognition compared to larger competitors.
• Dependence on regulatory approval for pharmaceutical products.
• Potential liquidity issues as an OTC listed company.

What Could Drive ALID Stock Higher?

ALID catalyst: Completion of Phase I clinical trials for ALID 10 and ALID 11, which could lead to significant advancements in PTSD treatment.

• Expansion of product distribution channels in the U.S. market to capture increasing consumer demand.
• Continuous development of innovative hemp-derived health products to enhance market competitiveness.
• Strategic partnerships aimed at enhancing market reach and product credibility.
• Monitoring and adapting to regulatory changes that could impact market opportunities.

What Are the Key Risks for ALID?

Financial-distress signal — its Altman Z-Score of -48.13 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Regulatory changes that could affect product approval and market access.
• Competition from established players in the cannabis industry impacting market share.
• Economic downturns that may reduce consumer spending on wellness products.
• Market volatility leading to fluctuations in stock price and investor sentiment.

What Are the Growth Opportunities for ALID?

• Expansion into U.S. Markets: Allied Corp. is strategically positioned to expand its market presence in the U.S., where the medical cannabis market is projected to grow at a CAGR of 22.9% through 2025. By enhancing its distribution channels and increasing product availability, the company can capture a significant share of this lucrative market, particularly with its innovative product offerings.
• Development of Pharmaceutical Products: The ongoing Phase I clinical trials for ALID 10 and ALID 11 targeting PTSD represent a critical growth opportunity. The global market for PTSD treatments is substantial, estimated to reach $7.5 billion by 2027. Successful development and approval of these products could provide Allied Corp. with a competitive edge and a new revenue stream.
• Innovative Product Development: Allied Corp.'s commitment to research and development in cannabinoid health solutions allows for the introduction of new products tailored to consumer needs. With the wellness trend driving demand for natural health products, the company can leverage its expertise to create innovative offerings that resonate with health-conscious consumers.
• Strategic Partnerships and Collaborations: Forming strategic alliances with healthcare providers, research institutions, and distribution partners can enhance Allied Corp.'s market reach and credibility. Collaborations can facilitate access to new markets and resources, accelerating growth and product development timelines.
• Regulatory Advancements: As regulations surrounding cannabis continue to evolve, Allied Corp. stands to benefit from increased acceptance and potential market expansion. Staying ahead of regulatory changes and adapting its business model accordingly can position the company favorably in the competitive landscape.

What Are ALID's Competitive Advantages?

• Innovative product development focused on cannabinoid health solutions.
• Established brand presence in the evolving cannabis market.
• Strong commitment to research and clinical trials for product efficacy.
• Diverse product portfolio catering to various consumer needs.
• Ability to adapt to regulatory changes in the cannabis industry.

What Does ALID Do?

Founded in 2013 and headquartered in Kelowna, Canada, Allied Corp. is a medical cannabis production company that engages in the research, development, and production of cannabinoid health solutions primarily in the United States. The company has evolved to offer a wide array of hemp-derived natural health products designed for various therapeutic applications. Among its flagship offerings are Liberty, a hemp-derived cannabidiol (CBD) tincture, and Tactical Hydration, a CBD-infused electrolyte replacement drink, which cater to health-conscious consumers. Allied Corp. also produces innovative products such as FIZZ Tablets, Battle Balm, and Quick Hit gummies under the Tactical Relief brand. Additionally, its Equilibrium Bio brand features Hydrosport CBD Drink and tinctures, while the MaXXa brand includes skincare products like Skin Structure and Eye Recover. Currently, Allied Corp. is advancing its pharmaceutical pipeline with ALID 10 and ALID 11, which are in Phase I clinical trials aimed at treating post-traumatic stress disorder (PTSD). This diversification into pharmaceuticals highlights the company's commitment to expanding its market presence and addressing unmet medical needs. As the cannabis industry continues to grow, Allied Corp. positions itself as a key player with a focus on innovation and quality in the rapidly evolving landscape of cannabinoid-based health solutions.

What Products and Services Does ALID Offer?

• Research, develop, and produce cannabinoid health solutions.
• Offer a variety of hemp-derived natural health products.
• Provide CBD-infused drinks, tinctures, and topical applications.
• Develop pharmaceutical products targeting specific health conditions.
• Focus on innovation and quality in product offerings.
• Engage in clinical trials for new therapeutic solutions.

How Does ALID Make Money?

• Generate revenue through the sale of hemp-derived health products.
• Develop pharmaceutical products for specific medical conditions.
• Leverage research and development to create innovative product lines.
• Expand distribution channels to reach a wider consumer base.
• Engage in partnerships to enhance product credibility and market presence.

What Industry Does ALID Operate In?

The cannabis industry, particularly the medical segment, is experiencing rapid growth, driven by increasing legalization and acceptance of cannabis products across various jurisdictions. Allied Corp. operates within this dynamic environment, competing against established players and new entrants in the specialty and generic drug manufacturing sector. The company's focus on cannabinoid health solutions positions it well to capitalize on the growing demand for natural health products and innovative therapies in the healthcare industry.

Who Are ALID's Key Customers?

• Health-conscious consumers seeking natural health products.
• Individuals with specific health conditions looking for cannabinoid solutions.
• Retailers and distributors of wellness products.
• Healthcare professionals recommending cannabinoid therapies.
• Patients participating in clinical trials for new products.

Company Profile

Allied Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Kelowna, CA. The company is led by CEO Michael Moses. ALID has traded publicly since 2019.

Return on equity for Allied Corp. stands at 261.4%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.05 means current liabilities exceed short-term assets, a liquidity point worth watching.

Allied Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -48.13 places it in the distress zone, a signal of elevated financial risk.

The most recent 2 insider filings for Allied Corp. break down as 0 sales and 2 purchases. On net that is roughly 80K shares acquired (about $37K) — insiders putting money in tends to read as conviction.

ALID Financials

ALID Latest News

ALID Analyst Consensus

ALID MoonshotScore

ALID Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources